Fundz

Scilex Holding Company Announces The Consummation Of The Previously Announced Purchase Of All Of The Scilex Common Shares, Preferred Shares And Warrants Owned By Sorrento Therapeutics, Inc.

PRIVATESep 21, 2023

Acquiring Company

Nanoscope Therapeutics

Acquired Company

Warrants

DallasFranceDallasBiotechnologyHealth CareMedicalTherapeuticsBiotechnologyHealth CareMedicalTherapeutics

Description

Scilex Holding Company (Nasdaq: SCLX, “Scilex” or “Company”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, announced the consummation of the previously announced purchase of securities from Sorrento Therapeutics, Inc. (OTC: SRNEQ, “Sorrento”).

Who to call at Nanoscope Therapeutics, and when

When Nanoscope Therapeutics changes hands, the new owners review vendors, systems and leadership. That is when the door opens.

  • An alert the day Nanoscope Therapeutics raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at Nanoscope Therapeutics, from your own LinkedIn network
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Company Information

Company

Nanoscope Therapeutics

Location

1312 BROWN TRAIL

Dallas, Texas, United States

About

Nanoscope Therapeutics is developing mutation-agnostic, sight-restoring optogenetic therapies for the millions of patients blinded by retinal degenerative diseases for which no treatment currently exists. Following positive end-of-study results from the RESTORE Phase 2b multicenter, randomized, double-masked, sham-controlled clinical trial for RP (NCT04945772), the company announced its plan to initiate a BLA submission for MCO-010 to treat RP in H1 2025. The company has completed the Phase 2 STARLIGHT trial of MCO-010 therapy in Stargardt patients (NCT05417126) and plans to initiate a Phase 3 registrational trial, also in the first half of 2025. MCO-010 has received FDA Fast Track designations and FDA orphan drug designations for both RP and Stargardt. Preclinical programs include an IND-ready non-viral laser-delivered MCO-020 asset for GA, as well as an AAV asset for Leber Congenital Amaurosis, in IND-enabling studies.

AI made execution free. Knowing first is the whole game now.

Fundz sees it the moment Nanoscope Therapeutics makes an acquisition, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Related People

Samuel
Likely contact at this company
••••••••@••••••••

See Samuel's verified email →

Khandan
Likely contact at this company
••••••••@••••••••

See Khandan's verified email →

Create an account to reveal verified emails
Predictive Intelligence
Strategic

ML-powered predictions for Nanoscope Therapeutics's next move

Learn about Strategic plan

Frequently asked

Who acquired Warrants?

Warrants was acquired by Nanoscope Therapeutics, based in Dallas. The deal was reported on September 21, 2023. Nanoscope Therapeutics is developing mutation-agnostic, sight-restoring optogenetic therapies for the millions of patients blinded by retinal degenerative diseases for which no treatment currently exists. Nanoscope Therapeutics is privately held and operates in Biotechnology.

When did Nanoscope Therapeutics acquire Warrants?

Nanoscope Therapeutics's acquisition of Warrants was reported on September 21, 2023. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.

What does Warrants do?

This website is for sale! warrants.fr is your first and best source for all of the information you’re looking for. From general topics to more of what you would expect to find here, warrants.fr has it all. We hope you find what you are searching for! It is privately held, and is based in France.

This company was part of an acquisition. Fundz tracks who bought whom, and who to call on both sides.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include FundzWatch™ for automated website change detection, Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.